BVS vs CVS: fair value comparison
Bioventus Inc. and CVS Health Corporation · Updated 2026-08-31
BVS currently screens as fairly valued while CVS screens as overvalued. Within Healthcare, BVS currently sits closer to the top of our discount ranking. BVS carries the stronger quality grade.
| BVS | CVS | |
|---|---|---|
| Verdict | Fairly valued | Overvalued |
| Last price | $13.47 | $93.06 |
| 12-month range | $6.56–$13.47 | $72.49–$105.37 |
| Sector rank | #86 of 113 Healthcare | #88 of 113 Healthcare |
| Quality grade | D | F |
| Momentum grade | B | — |
| Leverage | Moderate | Moderate |
| Margin trend | — | Stable |
| Revenue growth | — | Modest |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: BVS fair value analysis · CVS fair value analysis